The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
accepted:
28
06
2021
pubmed:
29
7
2021
medline:
4
2
2022
entrez:
28
7
2021
Statut:
ppublish
Résumé
In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sclerosis, including beta interferon, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, cladribine, natalizumab, alemtuzumab, and ocrelizumab. We review the proposed causal mechanisms described in the literature and we also address issues like use of DMTs in patients with viral hepatitis or liver cirrhosis. Most data emerged in the post-marketing phase by reports to national pharmacovigilance agencies and published case reports or case series. Serious liver adverse events are rare, but exact incidence is largely unknown, as are predictive factors. Unfortunately, none of the DMTs currently available for the treatment of multiple sclerosis is free of potential hepatic toxic effects. Cases of acute liver failure have been reported for beta-interferon, fingolimod, natalizumab, alemtuzumab, and ocrelizumab by different mechanisms (idiosyncratic reaction, autoimmune hepatitis, or viral reactivation). Patients with multiple sclerosis should be informed about possible hepatic side effects of their treatment. Most cases of liver injury are idiosyncratic and unpredictable. The specific monitoring schedule for each DMT has been reviewed and the clinician should be ready to recognize clinical symptoms suggestive for liver injury. Not all DMTs are indicated in cirrhotic patients. For some DMTs, screening for hepatitis B virus and hepatitis C virus is required before starting treatment and a monitoring or antiviral prophylaxis schedule has been established. Beta interferon, glatiramer acetate, natalizumab, and alemtuzumab are relatively contraindicated in autoimmune hepatitis due to the risk of disease exacerbation. Many disease-modifying therapies (DMTs) are approved for multiple sclerosis treatment, but liver injury is a concern. Patients can experience transaminase elevation during DMT treatment, and in rare cases, idiosyncratic and unpredictable acute liver failure. Currently, it is not possible to predict or prevent serious liver-related adverse events. Furthermore, autoimmune hepatitis and viral reactivation can also occur during DMT treatments. Since adverse events are greatly underreported, it is important to report cases of serious liver-related adverse events in the literature with adequate causality documentation to better understand the liver safety profiles of DMTs.
Autres résumés
Type: plain-language-summary
(eng)
Many disease-modifying therapies (DMTs) are approved for multiple sclerosis treatment, but liver injury is a concern. Patients can experience transaminase elevation during DMT treatment, and in rare cases, idiosyncratic and unpredictable acute liver failure. Currently, it is not possible to predict or prevent serious liver-related adverse events. Furthermore, autoimmune hepatitis and viral reactivation can also occur during DMT treatments. Since adverse events are greatly underreported, it is important to report cases of serious liver-related adverse events in the literature with adequate causality documentation to better understand the liver safety profiles of DMTs.
Identifiants
pubmed: 34319570
doi: 10.1007/s40263-021-00842-9
pii: 10.1007/s40263-021-00842-9
pmc: PMC8354931
doi:
Substances chimiques
Immunologic Factors
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
861-880Informations de copyright
© 2021. The Author(s).
Références
Neurology. 2017 Sep 12;89(11):1107-1116
pubmed: 28835401
Drug Saf. 2014 Nov;37 Suppl 1:S9-17
pubmed: 25352324
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304
pubmed: 22056965
Mult Scler Relat Disord. 2020 Feb;38:101871
pubmed: 31786463
J Clin Pharmacol. 2006 Feb;46(2):149-56
pubmed: 16432266
Neurology. 2014 Jul 1;83(1):78-86
pubmed: 24898925
Neurol Neurochir Pol. 2015;49(6):451-5
pubmed: 26652882
Eur J Haematol. 2008 May;80(5):381-5
pubmed: 18221389
Mult Scler. 2010 Mar;16(3):342-50
pubmed: 20106943
N Engl J Med. 2012 Sep 20;367(12):1098-107
pubmed: 22992073
Drug Saf. 2003;26(11):815-27
pubmed: 12908850
Lancet. 2012 Nov 24;380(9856):1819-28
pubmed: 23122652
Neurology. 1996 Jan;46(1):12-8
pubmed: 8559358
Mult Scler. 2018 Mar;24(3):350-353
pubmed: 28273779
J Neurol. 2020 Nov;267(11):3343-3353
pubmed: 32583052
Expert Opin Drug Saf. 2015 Jan;14(1):161-70
pubmed: 25382392
Blood. 2004 Aug 15;104(4):948-55
pubmed: 15090452
BMC Res Notes. 2019 Aug 12;12(1):497
pubmed: 31405369
CNS Drugs. 2018 Oct;32(10):963-970
pubmed: 30022464
Drug Saf. 2000 Feb;22(2):149-59
pubmed: 10672896
J Neurol Neurosurg Psychiatry. 2016 May;87(5):468-75
pubmed: 26111826
Mult Scler Relat Disord. 2020 Nov;46:102572
pubmed: 33296971
N Engl J Med. 2006 Mar 2;354(9):911-23
pubmed: 16510745
Lancet. 2009 Oct 31;374(9700):1503-11
pubmed: 19815268
J Clin Epidemiol. 1993 Nov;46(11):1323-30
pubmed: 8229110
Br J Haematol. 2010 Feb;148(3):484-6
pubmed: 19874308
Mult Scler. 2005 Dec;11(6):691-3
pubmed: 16320729
Neurology. 1993 Apr;43(4):655-61
pubmed: 8469318
Eur J Haematol. 2005 Mar;74(3):254-8
pubmed: 15693796
Mult Scler. 2015 Jul;21(8):1025-35
pubmed: 25432952
Eur J Neurol. 2019 Mar;26(3):460-467
pubmed: 30320947
J Neuroimmunol. 2015 Dec 15;289:93-7
pubmed: 26616877
Neurology. 2004 Feb 24;62(4):628-31
pubmed: 14981183
Mult Scler. 2021 Mar;27(3):331-346
pubmed: 32940121
BMC Neurol. 2019 Jan 7;19(1):5
pubmed: 30616596
J Neurol. 2019 Apr;266(4):888-901
pubmed: 30730008
JAMA Neurol. 2017 Aug 1;74(8):961-969
pubmed: 28604916
N Engl J Med. 2007 Jun 21;356(25):2622-9
pubmed: 17582072
Clin Ther. 2017 Aug;39(8):1671-1679
pubmed: 28751099
Acta Neurol Belg. 2018 Jun;118(2):331-333
pubmed: 29713905
World J Hepatol. 2015 Mar 27;7(3):344-61
pubmed: 25848463
Ann Hepatol. 2006 Jan-Mar;5(1):56-9
pubmed: 16531969
Neurology. 2006 Oct 10;67(7):1242-9
pubmed: 16914693
J Clin Pharm Ther. 2012 Dec;37(6):724-5
pubmed: 22642738
N Engl J Med. 2018 Sep 13;379(11):1017-1027
pubmed: 30207920
Neurology. 1999 Nov 10;53(8):1622-7
pubmed: 10563602
Mult Scler. 2017 Feb;23(2):253-265
pubmed: 27207449
BMC Med. 2016 Feb 04;14:10
pubmed: 26843061
Mult Scler. 2009 Feb;15(2):219-28
pubmed: 18755819
Mult Scler Relat Disord. 2020 Feb;38:101504
pubmed: 31733426
Clin Neuropharmacol. 2018 Jul/Aug;41(4):129-135
pubmed: 29927805
J Clin Pharmacol. 2012 Dec;52(12):1879-90
pubmed: 22174429
Mult Scler. 2012 Sep;18(9):1278-89
pubmed: 22307384
Lancet Neurol. 2014 Mar;13(3):257-67
pubmed: 24502830
Gastroenterology. 2015 Jan;148(1):221-244.e3
pubmed: 25447852
Mult Scler Relat Disord. 2019 Apr;29:157-167
pubmed: 30885374
Mult Scler. 2021 Mar;27(3):347-359
pubmed: 32940128
N Engl J Med. 2008 Oct 23;359(17):1786-801
pubmed: 18946064
J Hepatol. 2019 Jun;70(6):1222-1261
pubmed: 30926241
J Neurol. 2016 Apr;263(4):784-91
pubmed: 26914926
Drug Metab Dispos. 2011 Feb;39(2):191-8
pubmed: 21045201
N Engl J Med. 2010 Feb 4;362(5):402-15
pubmed: 20089954
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(2):e72
pubmed: 25815364
Neurology. 2001 Jun 12;56(11):1496-504
pubmed: 11402106
Lancet Neurol. 2014 Mar;13(3):247-56
pubmed: 24461574
Neurology. 2006 Jun 27;66(12):1954-5
pubmed: 16801674
Mult Scler. 2011 Mar;17(3):361-7
pubmed: 21148660
Hepatology. 2020 Aug;72(2):671-722
pubmed: 31863477
Open Forum Infect Dis. 2018 Dec 26;6(1):ofy356
pubmed: 30697576
Neurol Neuroimmunol Neuroinflamm. 2016 Apr 29;3(3):e228
pubmed: 27213173
Hepatology. 2016 Oct;64(4):1367-9
pubmed: 27228386
J Neurol. 2007 Jun;254(6):816-7
pubmed: 17351724
Brain Behav. 2018 Jun;8(6):e00968
pubmed: 29729087
CNS Drugs. 2020 Sep;34(9):973-988
pubmed: 32710396
Neurology. 2016 Mar 8;86(10):920-30
pubmed: 26865517
J Neurol. 2018 Nov;265(11):2494-2505
pubmed: 29525836
Neurology. 2014 May 20;82(20):1846-7
pubmed: 24843037
Mult Scler. 2011 May;17(5):578-93
pubmed: 21228029
Hepatology. 2012 Dec;56(6):2420-3
pubmed: 23175167
Lancet. 2008 Oct 25;372(9648):1447-8
pubmed: 18970966
PLoS One. 2014 Feb 03;9(2):e87379
pubmed: 24498318
Mult Scler. 2016 Aug;22(9):1215-23
pubmed: 26514979
J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668
pubmed: 32234967
Lancet Neurol. 2014 Jun;13(6):545-56
pubmed: 24685276
Lancet Neurol. 2019 Oct;18(10):973-980
pubmed: 31375366
Mult Scler. 2009 Nov;15(11):1378-9
pubmed: 19965562
N Engl J Med. 2017 Jan 19;376(3):280-282
pubmed: 28001486
Transpl Int. 2008 May;21(5):502-4
pubmed: 18167153
J Neuroimmunol. 2015 Aug 15;285:13-5
pubmed: 26198913
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
Am J Gastroenterol. 2008 Aug;103(8):2147-8; author reply 2148
pubmed: 18796115
N Engl J Med. 2012 Jan 26;366(4):339-47
pubmed: 22276823
N Engl J Med. 2006 Mar 2;354(9):899-910
pubmed: 16510744
Open Forum Infect Dis. 2018 Jul 16;5(8):ofy174
pubmed: 30094293
Clin Neuropharmacol. 2019 Sep/Oct;42(5):163-166
pubmed: 31348014
BMJ Case Rep. 2009;2009:
pubmed: 21686565
BMJ Case Rep. 2017 Jan 31;2017:
pubmed: 28143860
Am J Gastroenterol. 2002 Mar;97(3):767-8
pubmed: 11922585
Hepatology. 2016 Feb;63(2):590-603
pubmed: 26517184
Neurol Neuroimmunol Neuroinflamm. 2019 Jul 11;6(5):
pubmed: 31454772
Dig Dis Sci. 2013 Jun;58(6):1766-75
pubmed: 23377559
Mult Scler. 2018 Oct;24(12):1594-1604
pubmed: 28870107
Neurology. 2001 May 22;56(10):1416
pubmed: 11376205
Neurology. 2015 Apr 14;84(15):1582-91
pubmed: 25795646
CNS Drugs. 2013 Dec;27(12):1103-23
pubmed: 24198223
J Patient Rep Outcomes. 2017;1(1):1
pubmed: 29757324
Mult Scler Relat Disord. 2016 Sep;9:155-7
pubmed: 27645365
J Neurol Neurosurg Psychiatry. 2004 May;75(5):706-10
pubmed: 15090564
Neurology. 2002 Nov 26;59(10):1496-506
pubmed: 12451188
Ann Hepatol. 2015 Mar-Apr;14(2):273-80
pubmed: 25671839
Lancet. 2012 Nov 24;380(9856):1829-39
pubmed: 23122650
Br J Dermatol. 2003 Aug;149(2):363-9
pubmed: 12932244
N Engl J Med. 2020 Aug 6;383(6):546-557
pubmed: 32757523
Gastroenterol Hepatol. 2015 Apr;38(4):280-1
pubmed: 25042243
Neurology. 2004 Sep 28;63(6):1142-3; author reply 1142-3
pubmed: 15452330
Ann Hepatol. 2014 Nov-Dec;13(6):827-9
pubmed: 25332270
Neurology. 2013 Aug 27;81(9):850-2
pubmed: 23884038
Mult Scler. 2014 May;20(6):705-16
pubmed: 24126064
Expert Opin Drug Saf. 2014 Oct;13(10):1305-17
pubmed: 25134421
PLoS One. 2017 Apr 28;12(4):e0176174
pubmed: 28453541
BMC Neurol. 2017 Aug 7;17(1):150
pubmed: 28784108
Drugs. 2020 Dec;80(18):1901-1928
pubmed: 33247831
Mult Scler Relat Disord. 2013 Jan;2(1):57-9
pubmed: 25877455
Ther Adv Neurol Disord. 2019 Mar 27;12:1756286419835077
pubmed: 30944584
Neurol Neuroimmunol Neuroinflamm. 2019 Mar 07;6(3):e548
pubmed: 30882022
J Neurol. 2020 Aug;267(8):2362-2371
pubmed: 32350647
J Neurol. 2016 Aug;263(8):1626-32
pubmed: 27260297
Brain Behav. 2017 Aug 29;7(10):e00804
pubmed: 29075564
Lancet. 2016 Mar 12;387(10023):1075-1084
pubmed: 26827074
Br J Clin Pharmacol. 2004 Feb;57(2):199-208
pubmed: 14748819
Neurology. 1998 Feb;50(2):570-1
pubmed: 9484407
Transpl Int. 2007 Dec;20(12):1077-9
pubmed: 17937765
Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S90-4
pubmed: 24321165
Mult Scler. 2021 Feb;27(2):239-249
pubmed: 32141376
Clin Ther. 2015 Oct 1;37(10):2366-80
pubmed: 26365096
Mult Scler Relat Disord. 2018 Aug;24:42-46
pubmed: 29906666
Ann Neurol. 1996 Mar;39(3):285-94
pubmed: 8602746
Lancet. 1996 Jul 13;348(9020):129
pubmed: 8676694
Mult Scler Relat Disord. 2018 Feb;20:6-8
pubmed: 29272733
Mult Scler. 2018 Sep;24(10):1383-1385
pubmed: 29473796
Eur J Neurol. 2011 Jul;18(7):e78-9
pubmed: 21658156
Ther Adv Neurol Disord. 2019 Sep 25;12:1756286419878324
pubmed: 31598139
Lancet Neurol. 2018 May;17(5):405-415
pubmed: 29545067
Gastroenterol Hepatol. 2004 Nov;27(9):521-4
pubmed: 15544737
Mult Scler Relat Disord. 2014 Nov;3(6):732-4
pubmed: 25891553
Neurol Neuroimmunol Neuroinflamm. 2018 Jul 11;5(5):e477
pubmed: 30027104
Intern Med. 2017;56(14):1897-1901
pubmed: 28717089
J Neurol. 2005 Jul;252(7):855-6
pubmed: 15742101
N Engl J Med. 2011 Oct 6;365(14):1293-303
pubmed: 21991951
Gastroenterology. 2017 May;152(6):1297-1309
pubmed: 28219691
Mult Scler Relat Disord. 2014 Mar;3(2):266-8
pubmed: 25878015
Nat Rev Neurol. 2016 Apr;12(4):217-33
pubmed: 26943779
Am J Gastroenterol. 2007 Nov;102(11):2606-7
pubmed: 17958769
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Neurol Sci. 2017 Jan;38(1):53-59
pubmed: 27757552
CNS Drugs. 2014 Sep;28(9):817-24
pubmed: 25011422
Hepatogastroenterology. 2002 Nov-Dec;49(48):1686-7
pubmed: 12397766
Hepatology. 2021 Jan;73(1):460-463
pubmed: 32583445
CNS Drugs. 2013 Nov;27(11):971-88
pubmed: 24129744
Acta Neurol Belg. 2016 Mar;116(1):99-100
pubmed: 26141739
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
Mult Scler. 2007 Jul;13(6):820
pubmed: 17613614
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
Curr Drug Saf. 2012 Apr;7(2):186-8
pubmed: 22873505
Aliment Pharmacol Ther. 2010 May;31(9):1028-35
pubmed: 20163378
Lancet. 2017 Apr 1;389(10076):1347-1356
pubmed: 27889192
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
JAMA Neurol. 2019 Jul 1;76(7):866-867
pubmed: 30958517
Histopathology. 2015 Mar;66(4):605-7
pubmed: 24796493
N Engl J Med. 2012 Sep 20;367(12):1087-97
pubmed: 22992072
Mult Scler Relat Disord. 2015 Nov;4(6):495-8
pubmed: 26590653
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
Lancet. 1998 Nov 7;352(9139):1498-504
pubmed: 9820297
Lancet Neurol. 2008 Oct;7(10):903-14
pubmed: 18789766
Ther Adv Neurol Disord. 2017 Nov;10(11):367-372
pubmed: 29090021
Neurology. 2017 Sep 12;89(11):1117-1126
pubmed: 28835403
J Med Virol. 2006 Dec;78(12):1560-3
pubmed: 17063522
Lancet Neurol. 2014 Oct;13(10):977-86
pubmed: 25192851
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S71-S82
pubmed: 29447988
Eur J Neurol. 2007 Nov;14(11):1266-74
pubmed: 17956447
Mult Scler. 2017 Dec;23(14):1947-1949
pubmed: 28086032
Ann Neurol. 2007 Jan;61(1):14-24
pubmed: 17262850
J Rheumatol. 2016 May;43(5):869-74
pubmed: 26879359
Mult Scler. 2013 Aug;19(9):1234-5
pubmed: 23069876
Expert Rev Neurother. 2012 Mar;12(3):335-41
pubmed: 22364332
Lancet Neurol. 2012 Jan;11(1):33-41
pubmed: 22146409
BMC Neurol. 2019 Jul 12;19(1):159
pubmed: 31299922
Mult Scler. 2004 Jun;10(3):298-301
pubmed: 15222695
Mult Scler. 2020 May;26(6):737-740
pubmed: 32298205
J Clin Neurosci. 2019 Feb;60:158-160
pubmed: 30348589
Neurotherapeutics. 2007 Oct;4(4):647-53
pubmed: 17920545
J Neurol. 2018 Aug;265(8):1850-1859
pubmed: 29948245
PLoS One. 2020 Apr 2;15(4):e0230846
pubmed: 32240213
J Investig Med High Impact Case Rep. 2013 Dec 17;1(4):2324709613517493
pubmed: 26425591
Dig Liver Dis. 2012 Apr;44(4):356-7
pubmed: 22154948
Lancet Neurol. 2009 Oct;8(10):889-97
pubmed: 19729344